Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

NCT02525237 is registered in ClinicalTrials.gov with Qingdao Municipal Hospital as lead sponsor.

NCT NCT02525237
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02525237 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Lead sponsor
Qingdao Municipal Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
August 31, 2015
Completion date
August 31, 2017
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer